share_log

Canaccord Genuity Maintains Buy on Cartesian Therapeutics, Raises Price Target to $43

Benzinga ·  Jul 3 10:23

Canaccord Genuity analyst John Newman maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and raises the price target from $38 to $43.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment